This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.
Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe
by Zacks Equity Research
Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.
Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails
by Zacks Equity Research
Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Here's Why You Should Retain ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment toward clinical studies. However, limited commercial expertise is a woe.
Myriad Genetics (MYGN) Makes Progress in Precision Oncology
by Zacks Equity Research
Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.
Reasons to Add Allscripts (MDRX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.
Catalent's (CTLT) New Project Completion Expands Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.
Cardinal Health (CAH) Unveils the First Surgical Incise Drape
by Zacks Equity Research
Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.
AMN vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.
Walgreens (WBA), Village MD Plan to Expand Into New Hampshire
by Zacks Equity Research
Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $106.13, marking a -1.18% move from the previous day.
Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Is AMN Healthcare (AMN) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AMN Healthcare (AMN).
Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?
by Zacks Equity Research
Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.